Method of attenuating reactions to skin irritants

Details Method of attenuating reactions to skin irritants Method of attenuating reactions to skin irritants

2002-03-26

2008-09-02

Richter, Johann (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S025000, C536S004100, C536S017200

Reexamination Certificate

active

07419958

ABSTRACT:
The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.

REFERENCES:
patent: 4885285 (1989-12-01), Baschang et al.
patent: 5679347 (1997-10-01), Porcelli et al.
patent: 5705187 (1998-01-01), Unger
patent: 5851543 (1998-12-01), Korb et al.
patent: 5936076 (1999-08-01), Higa et al.
patent: 5945409 (1999-08-01), Crandall
patent: 6531453 (2003-03-01), Taniguchi et al.
patent: 6747010 (2004-06-01), Taniguchi et al.
patent: 2001/0051156 (2001-12-01), Zeng et al.
patent: 2002/0009465 (2002-01-01), Porcelli et al.
patent: 2003/0206914 (2003-11-01), Porcelli et al.
patent: 2004/0127429 (2004-07-01), Tsuji et al.
patent: 2004/0171522 (2004-09-01), Ilan
patent: 2004/0171527 (2004-09-01), Ilan et al.
patent: 2004/0171557 (2004-09-01), Ilan
patent: 2005/0159365 (2005-07-01), Serizawa et al.
patent: 198 41 794 (2000-03-01), None
patent: 0988860 (2000-03-01), None
patent: 0751780 (2003-09-01), None
patent: 5-331049 (1993-12-01), None
patent: 08116971 (1996-05-01), None
patent: H0-8116971 (1996-05-01), None
patent: 11-302155 (1999-11-01), None
patent: 2000-264825 (2000-09-01), None
patent: 2000-264829 (2000-09-01), None
patent: WO 99/29293 (1999-06-01), None
patent: WO 00/02583 (2000-01-01), None
patent: WO 02/051986 (2002-07-01), None
patent: WO 02/051986 (2002-09-01), None
patent: WO 2004/028475 (2004-04-01), None
patent: WO 2005/014008 (2005-02-01), None
patent: WO 2005/014008 (2005-11-01), None
patent: WO 2006/002132 (2006-01-01), None
DiSepio et al. Novel approaches for the treatment of psoriasis. Drug Discovery Today 1999, 4(5), 222-231.
El-Gabalawy et al. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2002, 4(suppl 3), S297-S301.
Erlebacher et al. Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system. Journal of Clinical Investigation 2004, 114(1), 39-48.
Peltier, M.R. Immunology of term and preterm labor Reproductive Biology and Endocrinology 2003, 1:122 pp. 1-11.
Maruyama et al. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol) Biochimica et Biophysica Acta 1992, 1128, 44-49.
Filion et al. Anti-inflammatory activity of cationic lipids British Journal of Pharmacology 1997, 122, 551-557.
Kawano et al. CD1d-restricted and TCR-mediated activation of V-alpha-14 NKT cells by glycosylceramides Science 1997, 278(28), 1626-1629.
Nieda et al. Activation of human V-alpha-24NKT cells by alpha-glycosylceramide in a CD1d-restricted and V-alpha-24TCR-mediated manner Human Immunology 1999, 60, 10-19.
Kobayashi et al. Bioorganic and Medicinal Chemistry 1996, 4(4), 615-519.
Abstact: Derwent-ACC-No. 1996-280770 abstacting JP 08116971A.
Trautmann et al. Trends in Immunology, vol. 22, No. 10, Oct. 1, 2001, pp. 530-532.
Bonish et al. The Journal of Immunology 2000, 165, 4076-4085.
Forestier et al. Journal of Immunology 2005, 175, 763-770.
Elkhal et al. J. Allergy Clin. Immunol. 2006, 118, 1363-8.
B. Bonish et al., J. Immunol., 165:4076-4085 (2000).
V. Briken et al., Immunology, 12:517-525 (2000).
T. Kawano et al., Science, 278:1626-1629 (1997).
M. Kronenberg et al., Proc. Natl. Acad. Sci. USA, 98(16):2950-2952 (2001).
T. Kupper, J. Clin. Invest., 86:1783-1789 (1990).
M. Mempel et al., Am. J. Pathol. 157(2):509-523 (2000).
O. Naidenko et al., J. Exp. Med., 190 (8):1069-1079 (1999).
Y. Naumov et al., PNAS, 98(24):13838-13843 (2001).
B. Nickoloff et al., Arch. Dermatol., 135:546-552 (1999).
B. Nickoloff et al., J. Dermatol. Sci. 24:212-225 (2000).
F-D Shi et al., PNAS, 98(12):6777-6782 (2001).
M. Sugita et al., Immunology, 12:511-516 (2000).
Apostolou, I. et al.; Proc. Natl. Acad. Sci. USA; 96:5141-5146 (Apr. 1999).
Fayyazi, A. et al.; Arch Dermatol. Res.; 291:485-490 (1999).
Ito, Katsura et al.; PNAS; 97(2):740-744 (Jan. 18, 2000).
Kaneko, Yoshikatsu et al.; J. Exp. Med.; 191(1):105-114 (Jan. 3, 2000).
Magnan, A. et al.; Allergy; 55:286-290 (2000).
Wollenberg, A. et al.; Allergy; 55:205-213 (2000).
Amano, et al. CD1 expression defines subsets of follicular and marginal zone B cells in the spleen: beta 2-microglobulin-dependent and independent forms. J Immunol. Aug. 15, 1998;161(4):1710-7.
Bendig, M. Humanization of Rodent Monoclonal Antibodies by CDR Grafting. Methods A Companion To Methods In Enzymology. 1995; 8:83-93.
Berkow, et al. Ed. The Merck Manual of Diagnosis and Therapy. 16th Ed. Merck Research Laboratories. 1992: 1316-1321.
Blumberg, et al. Structure and Function of the CD1 Family of MHC-like Cell Surface Proteins. Immunological Reviews. 1995; 147 (1):5-29.
Brossay, et al. Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands. Immunol Rev. Jun. 1998;163:139-50.
Chan, et al. Deficiency in beta(2)-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) mice: an example of disease regulation at the organ level. J Immunol. Sep. 1, 2001;167(5):2985-90.
Chang, et al. The synthesis and biological characterization of a ceramide library. J Am Chem Soc. Mar. 6, 2002;124(9):1856-7.
Hong, et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev. Jun. 1999;169:31-44.
Hughes, D. Therapeutic antibodies make a comeback. Drug Discovery Today. 1998; 3(10):439-442.
Jahng, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. Dec. 17, 2001;194(12):1789-99.
Joyce, et al. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science. Mar. 6, 1998;279(5356):1541-4.
Kotzin, et al. SystemicLupus erythematosus. Cell. May 3, 1996;85(3):303-6.
Lehuen, et al. Overexpression of natural killer T cells protects Valpha 14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med. Nov. 16, 1998;188(10):1831-9.
Park, et al. Inhibitory activity of a ceramide library on interleukin-4 production from activated T cells. Bioorg Med Chem. Apr. 1, 2005;13(7):2589-95.
Park, et al. Innate and adaptive functions of the CD1 pathway of antigen presentation. Semin Immunol. Oct. 1998;10(5):391-8.
Sharif, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. Sep. 2001;7(9):1057-62.
Singh, et al. Genetic deletion of CD1 inLupus: evidence of a regulatory role. Arth. Rheum. Suppl. 2001; 44:283.
Swain, et al. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol. Mar. 1984;132(3):1118-23.
Swain, S. T cell subsets and the recognition of MHC class. Immunol Rev. 1983;74:129-42.
Vaughan, et al. Human antibodies by design. Nat Biotechnol. Jun. 1998;16(6):535-9.
Wofsy, et al. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. Feb. 1, 1985;161(2):378-91.
Yang, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model ofLupus nephritis. J Immunol. Aug. 15, 2003;171(4):2142-53.
Yang, et al. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol. Oct. 15, 2003;171(8):4439-46.
Zeng, et al. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbatingLupus..J Clin Invest. Oct. 2003;112(8):1211-22.
Zeng, et al. Subsets of transgenic T cells that recognize CD1 induce or prevent murineLupus: role of cyt

Affiliated with

Also associated with

Rating

Method of attenuating reactions to skin irritants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of attenuating reactions to skin irritants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of attenuating reactions to skin irritants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3984137